The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | BiTEs in the early treatment of multiple myeloma
Hareth Nahi, MD, PhD, of the Karolinska Institutet, Stockholm, Sweden, discusses the latest data on the use of bispecific T-cell engagers (BiTEs) in the treatment of multiple myeloma. Dr Nahi recommends that BiTEs are used as early as possible in the treatment of myeloma, commenting on data from Phase I and II studies which report response rates to other drugs of 20-35%, in comparison to response rates of 65-85% for patients with relapsed or refractory myeloma receiving BiTEs. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Transcript
I will try to discuss the position of the T-cell’s engagement in myeloma treatment in the near future. My recommendation will be to use them as early as possible. And the argumentation that I have, one, looking at historical data in single-agent myeloma drugs in Phase I to II studies, the response rates are between 20 to 35%, as to say, one-third of the patient will respond to, so, new single-agent myeloma drug...
I will try to discuss the position of the T-cell’s engagement in myeloma treatment in the near future. My recommendation will be to use them as early as possible. And the argumentation that I have, one, looking at historical data in single-agent myeloma drugs in Phase I to II studies, the response rates are between 20 to 35%, as to say, one-third of the patient will respond to, so, new single-agent myeloma drug.
While looking at these T-cell engager, we are using them in a very late stage patient. Often, they are refractory and penta-exposed. We see a response rate between 65, up to 85, as to say, they are very effective. And I will argue to use these drugs as early as possible, and try to minimize the time taken for this agent to reach the first-line treatment, but because I believe the most effective agents should be used in first-line in cancer patients.
Read more...
